I have seen this movie a million times. You look at a random cross-section of the market—ranging from legacy food behemoths to no-name shell companies—and the core theme is always about survival. The market does not care if you are a Swiss conglomerate or a biotech startup running on fumes; if you aren't delivering, you get tossed into the same scrap heap. Let's look at this bizarre group of misfits and figure out who is actually awake and who is just taking up space.

Let's start with the bloated giants. Nestle (NSRGY.US) recently saw its shares fall off a cliff after dismal North American sales. Their solution? Offloading half of their water business—including brands like Perrier—into a joint venture with Platinum Equity. This is stupid and here's why: they should have done this years ago. Now they are scrambling to dump a failing vitamin unit too. Meanwhile, French supermajor TotalEnergies (TTE.US) is just sitting there doing what massive oil companies do. It is highly profitable, sure, but entirely uninspiring in a market that demands constant evolution.

Then we have the old-school players shuffling deck chairs. Jardine Matheson (JMHLY.US) is trying to signal confidence with recent executive stock purchases and share buybacks, backed by a USD 735M interim profit. It's a nice little restructuring story, but hardly world-changing. Invesco (IVZ.US) is playing a similar game, hawking its Canadian funds and selling off Intelliflo to Carlyle for a couple hundred million. These are housekeeping moves, not bold strategic pivots.

Surprisingly, there are a couple of actual businesses in this mix. AvePoint (AVPT.US) is grinding it out in the enterprise software space, posting a 27% jump in SaaS revenue for Q2 2026 and deploying buybacks. In a sector where everyone is struggling to justify their valuations, putting up real Annual Recurring Revenue (ARR) numbers is refreshing. Over in hardware, Valens Semiconductor (VLN.US) axed 10% of its workforce earlier this year and just swapped out its auto division head to try and capitalize on ADAS tech. At USD 16.9M in recent quarterly revenue, they are at least trying to right the ship.

And finally, the bottom of the barrel. NextCure (NXTC.US) is burning through its last USD 20M in cash and orchestrating an all-stock reverse merger just to stay listed. Then you have absolute black holes like Founder Group (FGL.US), Stak (STAK.US), and SPAC shell Future Vision (FVN.US). Why are these even trading? Good luck with that. If you are throwing money at micro-caps with zero news flow, you deserve what happens next.

Stop pretending every ticker has a turnaround story. Some of these need to be taken private and put out of their misery.

This article does not constitute investment advice.